Key Takeaways From ASH 2024

EP: 1.Welcome to This OncLive Peer Exchange: Highlighting Key Abstracts From ASH 2024

EP: 2.Insights From the Comparative Efficacy and Safety of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel in Real-World Relapsed/Refractory Multiple Myeloma: A Retrospective Intention-to-Treat Analysis

EP: 3.Application of Real-World Evidence in Selecting CAR T in R/R MM

EP: 4.Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM

EP: 5.Choosing Between Bispecifics and CAR T: Real-World Implications in R/R MM

EP: 6.Future of Bispecifics and CAR T in R/R MM

EP: 7.Overview of the 5-Year Follow-Up Analysis From ZUMA-5: A Phase 2 Trial of Axi-Cel in R/R Indolent NHL

EP: 8.Key Takeaways From Iopofosine I 131 in Previously Treated Patients With Waldenstrom Macroglobulinemia (WM) in the CLOVER-WaM Trial

EP: 9.Overview of the Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients With Previously Untreated DLBCL Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial

EP: 10.Insights From Liso-cel Combined With Ibr for R/RCLL/SLL: Primary Results From the Open-Label, Phase 1/2 Transcend CLL 004 Study

EP: 11.Implications of BTK Inhibitors Combined With CAR-T in R/R CLL/SLL

EP: 12.Overview of ZUMA-2 Cohorts 1-3: Use of Brexu-cel in R/R MCL

EP: 13.Insights From Augmented Hyper-CVAD (AHCVAD), a Pediatric-Inspired Regimen for Adults Younger Than 50 Years With ALL

Now Viewing

EP: 14.Key Takeaways From ASH 2024

EP: 15.Looking Into the Future of AML Treatments

EP: 16.Looking Ahead For the Treatments of R/R MM

EP: 17.Recommendations For Future Clinical Trials in R/R MM

EP: 18.Treatment and Management of MM with Amyloidosis

EP: 19.Highlighting the Key Takeaways From ASH 2024

Video content above is prompted by the following:

The American Society of Hematology (ASH) 2024

Annual meeting showcased significant advancements poised to reshape the treatment landscape for hematologic malignancies. Key developments include the following:​

Novel Combination Therapies: Clinical trials presented at ASH 2024 highlighted the efficacy of new combination treatments.

• Acute Myeloid Leukemia (AML): A study involving patients with relapsed or refractory AML demonstrated an 82% overall response rate, with nearly half achieving complete remission using a regimen of revumenib (Revuforj), venetoclax (Venclexta), and decitabine and cedazuridine (Inqovi).
• Chronic Lymphocytic Leukemia: The AMPLIFY trial reported that fixed-duration combinations of acalabrutinib and venetoclax, with or without obinutuzumab, led to superior progression-free survival compared with traditional chemoimmunotherapy while maintaining a manageable adverse effect profile. ​

Immunotherapy Integration: The incorporation of immunotherapies is redefining treatment protocols:​

• B-cell Acute Lymphoblastic Leukemia: The plenary session unveiled that combining blinatumomab with chemotherapy achieved a 96% 3-year disease-free survival rate in pediatric patients, suggesting a new standard of care. ​
• Adult Acute Lymphoblastic Leukemia: Studies emphasized the role of immunotherapies like blinatumomab and inotuzumab in achieving minimal residual disease negativity, allowing for tailored, less chemotherapy-intensive strategies. ​

Advances in chimeric antigen receptor (CAR) T-Cell Therapy: CAR T-cell therapies continue to evolve:​

• Transformed Indolent Non-Hodgkin Lymphoma (tiNHL): Research indicated that CD19 CAR T therapy resulted in higher complete response rates and comparable survival outcomes in patients with tiNHL compared with those with aggressive large B-cell lymphoma, with a favorable safety profile. ​

Precision Medicine and Genetic Profiling: Emphasis on genetic and molecular profiling is enhancing treatment personalization.

• Mantle Cell Lymphoma: Trials like TRIANGLE demonstrated that integrating ibrutinib with chemoimmunotherapy and autologous stem cell transplant significantly improved failure-free survival, potentially redefining treatment protocols. ​
• Follicular Lymphoma: Bispecific antibodies, such as mosunetuzumab, are showing promise as first-line therapies, achieving high complete response rates with manageable adverse effects. ​

These developments from ASH 2024 highlight a dynamic shift toward more personalized, effective, and equitable treatments in hematologic malignancies, emphasizing the integration of novel therapies, precision medicine, and technological innovations in clinical practice.